top of page

JACLYN CHEN

SENIOR REGISTERED FOREIGN LAWYER                                         

OVERVIEW

Jaclyn Chen is a Senior Registered Foreign Lawyer in the capital markets department of DeHeng Hong Kong office. Jaclyn has extensive experience in capital markets and corporate transactions, with a particular focus on Hong Kong and U.S. initial public offerings, pre-IPO financings, mergers and acquisitions and regulatory compliance matters.

​

Jaclyn has advised issuers, sponsors and underwriters on a wide range of Hong Kong and U.S. capital markets transactions. She has particular experience in the life sciences and healthcare sectors, having advised numerous biotechnology and healthcare companies on their Hong Kong listings, including listings of biotechnology companies under Chapter 18A of the Hong Kong Listing Rules. She also has experience advising specialist technology companies under Chapter 18C of the Hong Kong Listing Rules.

​

Her experience covers the full lifecycle of capital markets transactions, including legal due diligence, prospectus and registration statement drafting, responding to comments from The Stock Exchange of Hong Kong Limited, the Securities and Futures Commission and the U.S. Securities and Exchange Commission, prospectus verification, underwriting arrangements, transaction documentation and post-listing regulatory compliance.

​

Prior to joining DeHeng Hong Kong, Jaclyn worked at leading international and PRC law firms, including Davis Polk & Wardwell LLP, O'Melveny & Myers LLP and Fangda Partners, where she advised clients on Hong Kong and U.S. capital markets transactions, mergers and acquisitions, private equity investments and other corporate matters.

WORK HIGHLIGHTS

Representative Matters

  • Advised on the Hong Kong IPO of Medtide Inc. (HKEX: 3880).

  • Advised on the Hong Kong IPO of PegBio Co., Ltd. (HKEX: 2565).

  • Advised on the Hong Kong IPO of Insilico Medicine (HKEX: 3696), a biotechnology company powered by generative artificial intelligence.

  • Advised on the Hong Kong IPO of TransThera Sciences (Nanjing), Inc. (HKEX: 2617).

  • Advised on the Hong Kong IPO of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 2315).

  • Advised on the Hong Kong IPO of Laekna, Inc. (HKEX: 2105).

  • Advised on the Hong Kong IPO of Cutia Therapeutics (HKEX: 2487).

  • Advised on the Hong Kong IPO of HighTide Therapeutics, Inc. (HKEX: 2511).

  • Advised on the proposed Hong Kong IPOs of Adlai Nortye (Nasdaq: ANL) and ImmVira.

  • Advised on the Hong Kong IPO of Beauty Farm Medical and Health Industry Inc. (HKEX: 2373).

  • Advised on the Hong Kong IPO of Yonghe Medical Group Co., Ltd. (HKEX: 2279).

  • Advised on the spin-off and Hong Kong IPO of Jinmao Property Services Co., Limited (HKEX: 0816).

  • Advised on the Hong Kong IPO of Jinxin Fertility Group Limited (HKEX: 1951).

 

EDUCATION BACKGROUND

  • Master of Science in Biotechnology, Hong Kong University of Science and Technology

  • Master of Laws, Columbia University

  • Master of Laws, London School of Economics and Political Science

  • Bachelor of Law, Xiamen University

 

PROFESSIONAL QUALIFICATIONS

  • Registered Foreign Lawyer in Hong Kong

  • Attorney admitted to the State Bar of California

  • PRC Lawyer Practicing Certificate

  • Board Secretary Qualification Certificate – STAR Market, Shanghai Stock Exchange

  • Board Secretary Qualification Certificate – ChiNext Market, Shenzhen Stock Exchange

bottom of page